Publication date: Jul 19, 2019
The US Food and Drug Administration this week issued final guidance concerning the submission of next-generation sequencing data from resistance assessments performed in the development of antiviral drugs.
|Antiviral Drugs||Antiviral drug|
- Genomics-Guided Immunotherapy for Precision Medicine in Cancer.
- Drug Development Panel – 2019 Stanford Medicine Big Data | Precision Health
- As precision medicine grows, so does the importance of clinical trial diversity
- Pharmacogenomics Clinical Annotation Tool (PharmCAT).